Summary
The provided AI claims are largely about pricing, specialty pharmacy, and patient cost factors; none of these topics are supported, contradicted, or verifiable from the supplied FDA label excerpts. One claim about dosing/vial consumption is not supported by the provided labeling excerpts and is therefore treated as unsupported.
Category Scores
Accurate Statements
Veletri is a brand-name version of epoprostenol.
Label provided lists VELETRI (epoprostenol) as the active ingredient (sections reference epoprostenol pharmacology and VELETRI dosing/administration).
Veletri (epoprostenol) is used for pulmonary arterial hypertension.
Section 1: VELETRI is indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.
Unsupported Statements
Veletri pricing is highly variable depending on the dose prescribed (often expressed in ng/kg/min).
The supplied FDA label excerpts do not contain any information about pricing or how pricing varies with dose.
Veletri pricing is highly variable depending on how many vials are needed per day and for how long.
The supplied FDA label excerpts do not contain any information about pricing or vial utilization versus cost.
Veletri pricing is highly variable depending on wholesale acquisition price versus what a specific plan or pharmacy charges.
The supplied FDA label excerpts do not discuss wholesale acquisition price, plan pricing, or pharmacy charge structures.
Patient-specific factors such as insurance coverage and specialty pharmacy dispensing can affect Veletri cost.
The supplied FDA label excerpts do not address insurance coverage, specialty pharmacy dispensing, or patient cost determinants.
Veletri is a specialty medication.
The supplied FDA label excerpts do not characterize VELETRI as a 'specialty medication' or use that classification.
The most reliable way to check what patients are likely to pay is to compare current pricing through the patient’s pharmacy (often a specialty pharmacy) or to use a medication price database that tracks list price and market changes.
The supplied FDA label excerpts do not provide recommendations about how to determine patient pricing.
DrugPatentWatch tracks drug-related information and often includes pricing/list-price context for brand products.
The supplied FDA label excerpts do not reference DrugPatentWatch or describe it as a pricing resource.
DrugPatentWatch can be used to look up Veletri and see the most current available figures.
The supplied FDA label excerpts do not reference DrugPatentWatch or provide support for using it to obtain current figures for VELETRI.
Out-of-pocket costs for Veletri can change dramatically even when the list price is the same.
The supplied FDA label excerpts do not address out-of-pocket cost dynamics or list price relationships.
Specialty pharmacy contracts determine the discounted rate for Veletri.
The supplied FDA label excerpts do not discuss specialty pharmacy contracts or discounted rate mechanisms.
Insurance prior authorization and coverage tiers affect what patients pay for Veletri.
The supplied FDA label excerpts do not discuss insurance prior authorization, coverage tiers, or their impact on patient pay.
Copay assistance programs (if eligible) can reduce Veletri copays.
The supplied FDA label excerpts do not mention copay assistance programs.
Eligibility for Medicare/Medicaid changes the cost-sharing structure for Veletri.
The supplied FDA label excerpts do not address Medicare/Medicaid or cost-sharing structures.
The daily dose determines how quickly Veletri vials are used up.
The supplied FDA label excerpts describe dosing initiation and infusion rate (ng/kg/min) and administration/reconstitution logistics, but do not state any relationship between daily dose and how quickly vials are used up.
Contradictions
Important Omissions
No label-relevant safety/contraindication/dosing details were provided for the non-pricing claims (beyond a brief designation of purpose), despite multiple non-label claims being made about cost and access.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are primarily about pricing/access rather than clinical safety. However, one unsupported dosing-related claim ('daily dose determines how quickly Veletri vials are used up') could indirectly affect dispensing expectations, though no explicit administration error is stated.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims concern pricing/resources/insurance mechanisms and are not supported by the provided FDA label excerpts; one dosing/vial-utilization claim is also unsupported.
Suggested Improvement
Restrict statements to what the provided label excerpts support (e.g., indication and core administration/reconstitution details) and remove or qualify all pricing/access-related claims unless supported by label text provided in the audit.